These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
139 related articles for article (PubMed ID: 16444378)
1. [Does the criterium of positivity for the immunohistochemical analysis of p53 in the confirmation of Barrett's dysplasia make any difference?]. Lopes CV; Pereira-Lima JC; Hartmann AA; Tonelotto E; Salgado K Arq Gastroenterol; 2005; 42(4):233-8. PubMed ID: 16444378 [TBL] [Abstract][Full Text] [Related]
2. Flow cytometric DNA analysis and p53 protein expression show a good correlation with histologic findings in patients with Barrett's esophagus. Giménez A; Minguela A; Parrilla P; Bermejo J; Pérez D; Molina J; García AM; Ortiz MA; Alvarez R; de Haro LM Cancer; 1998 Aug; 83(4):641-51. PubMed ID: 9708926 [TBL] [Abstract][Full Text] [Related]
6. Accumulation of p53 protein in normal, dysplastic, and neoplastic Barrett's oesophagus. Krishnadath KK; Tilanus HW; van Blankenstein M; Bosman FT; Mulder AH J Pathol; 1995 Feb; 175(2):175-80. PubMed ID: 7738712 [TBL] [Abstract][Full Text] [Related]
7. p53 expression in low grade dysplasia in Barrett's esophagus: correlation with interobserver agreement and disease progression. Skacel M; Petras RE; Rybicki LA; Gramlich TL; Richter JE; Falk GW; Goldblum JR Am J Gastroenterol; 2002 Oct; 97(10):2508-13. PubMed ID: 12385431 [TBL] [Abstract][Full Text] [Related]
8. Apoptosis and cell proliferation in the metaplasia-dysplasia-carcinoma-sequence of Barrett's esophagus. Halm U; Tannapfel A; Breitung B; Breidert M; Wittekind CW; Mössner J Hepatogastroenterology; 2000; 47(34):962-6. PubMed ID: 11020858 [TBL] [Abstract][Full Text] [Related]
9. p53 expression in Barrett's oesophagus, dysplasia, and adenocarcinoma using antibody DO-7. Symmans PJ; Linehan JM; Brito MJ; Filipe MI J Pathol; 1994 Jul; 173(3):221-6. PubMed ID: 7931842 [TBL] [Abstract][Full Text] [Related]
10. Immunohistochemical study of p53, c-erbB-2, and PCNA in barrett's esophagus with dysplasia and adenocarcinoma arising from experimental acid or alkaline reflux model. Kawaura Y; Tatsuzawa Y; Wakabayashi T; Ikeda N; Matsuda M; Nishihara S J Gastroenterol; 2001 Sep; 36(9):595-600. PubMed ID: 11578062 [TBL] [Abstract][Full Text] [Related]
11. p53 and Ki-67 in Barrett's carcinoma: is there any value to predict recurrence after circumferential endoscopic mucosal resection? Lopes CV; Mnif H; Pesenti C; Bories E; Monges G; Giovannini M Arq Gastroenterol; 2007; 44(4):304-8. PubMed ID: 18317648 [TBL] [Abstract][Full Text] [Related]
13. Evaluation of Barrett's esophagus with CK7, CK20, p53, Ki67, and COX2 expressions using chromoendoscopical examination. Çoban Ş; Örmeci N; Savaş B; Ekiz F; Ensari A; Kuzu I; Palabıyıkoğlu M Dis Esophagus; 2013; 26(2):189-96. PubMed ID: 22591041 [TBL] [Abstract][Full Text] [Related]
14. [Dysplasia in Barrett's esophagus--intra- and interobserver variability in histopathological diagnosis]. Lopes CV; Pereira-Lima JC; Hartmann AA; Tonelotto E; Salgado K Arq Gastroenterol; 2004; 41(2):79-83. PubMed ID: 15543378 [TBL] [Abstract][Full Text] [Related]
15. A comparative cytopathologic and histologic study of atypia, dysplasia, and adenocarcinoma in Barrett's esophagus. Geisinger KR; Teot LA; Richter JE Cancer; 1992 Jan; 69(1):8-16. PubMed ID: 1727677 [TBL] [Abstract][Full Text] [Related]
16. Dysplasia in Barrett's oesophagus: p53 immunostaining is more reproducible than haematoxylin and eosin diagnosis and improves overall reliability, while grading is poorly reproducible. Kaye PV; Ilyas M; Soomro I; Haider SA; Atwal G; Menon S; Gill S; Richards C; Harrison R; West K; Ragunath K Histopathology; 2016 Sep; 69(3):431-40. PubMed ID: 26918780 [TBL] [Abstract][Full Text] [Related]
17. Diagnosis and Management of Low-Grade Dysplasia in Barrett's Esophagus: Expert Review From the Clinical Practice Updates Committee of the American Gastroenterological Association. Wani S; Rubenstein JH; Vieth M; Bergman J Gastroenterology; 2016 Nov; 151(5):822-835. PubMed ID: 27702561 [TBL] [Abstract][Full Text] [Related]
18. COX-2, CDX2, and CDC2 immunohistochemical assessment for dysplasia-carcinoma progression in Barrett's esophagus. Villanacci V; Rossi E; Zambelli C; Galletti A; Cestari R; Missale G; Casa DD; Bassotti G Dig Liver Dis; 2007 Apr; 39(4):305-11. PubMed ID: 17307036 [TBL] [Abstract][Full Text] [Related]
19. Methylene blue chromoendoscopy for the detection of Barrett's esophagus in a Greek cohort. Kouklakis GS; Kountouras J; Dokas SM; Molyvas EJ; Vourvoulakis GP; Minopoulos GI Endoscopy; 2003 May; 35(5):383-7. PubMed ID: 12701007 [TBL] [Abstract][Full Text] [Related]
20. p53 gene mutation and protein accumulation during neoplastic progression in Barrett's esophagus. Bian YS; Osterheld MC; Bosman FT; Benhattar J; Fontolliet C Mod Pathol; 2001 May; 14(5):397-403. PubMed ID: 11353048 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]